Biocon Biologics Scores FDA Approval—A Biosimilar Shake-Up for Amgen, Patients, and Investors

Biocon Biologics secures FDA approval for Bosaya™ and Aukelso™, biosimilars to Prolia® and Xgeva®. What this means for patients, payers, and Amgen.

A Landmark for Indian Biologics

Biocon Biologics has secured U.S. FDA approval for two denosumab biosimilars — Bosaya™ and Aukelso™. These drugs, biosimilar to Amgen’s blockbuster brands Prolia® and Xgeva®, address critical needs in osteoporosis and oncology care.